About US
Contact us
-
CureVac in 'advanced' talks with EU to supply 225M coronavirus vaccine dosesOfficials in Europe have engaged some of the world's largest biopharma companies in COVID-19 vaccine supply talks, but now Germany’s CureVac is moving into advanced supply negotiations with the union2020/8/20
-
With Gilead's JAK inhibitor on the shelf, AbbVie's Rinvoq stands to gain big in rheumatoid arthritis: analystsWith its megamerger with Allergan in the books, AbbVie is focusing its growth on a stable of homegrown meds, including recent rheumatoid arthritis launch Rinvoq. Signs were looking good already—and a2020/8/20
-
Merck's Keytruda sets up Opdivo showdown with esophageal cancer victoryAfter archrival Opdivo from Bristol Myers Squibb posted a pair of esophageal cancer wins last week, Merck & Co.’s Keytruda is determined not to be left behind. The New Jersey drugmaker Wednesday2020/8/19
-
Roche, Regeneron join forces to more than triple manufacturing of COVID-19 antibody cocktailDespite hundreds of potential therapies for COVID-19 looking to make their case, very few have crossed the finish line. One promising candidate, Regeneron's two-antibody cocktail, has earned early pl2020/8/19
-
Mylan's Tecfidera generic launch jolts Biogen, putting billions at stakeDespite Biogen's intense effort to defend its big-selling multiple sclerosis drug Tecfidera, Mylan has cleared several hurdles to launch a copycat, and now it's doing just that. After an early FDAapp2020/8/18
-
Takeda to sell Japan consumer health unit to Blackstone for $2B-plus: reportsThe final—and the biggest—piece of Takeda’s $10 billion divestment plan could be wrapped up soon. The Japanese pharma isin the final stage of talksto sell its domestic consumer health business to U.S2020/8/18
-
New York wraps Allergan and Teva into ongoing opioid abuse probe with new civil chargesNew York Governor Andrew Cuomo may have been preoccupied with getting the COVID-19 pandemic under control in his state over the past few months, but that hasn’t stopped him from going after the opioi2020/8/17
-
Japanese CMO Bushu plugs $100M into broad expansion plans for 'Asia hub'Japanese contract manufacturer Bushu Pharmaceuticals has held a spot as the top company in its field following a big buyout six years ago. Now, with plans to become an "Asia hub" for pharmaceutical i2020/8/17
-
COVID-19 vaccine players will split $100B in sales and $40B in profits, with Moderna leading the way: analystWhen longtime Evercore ISI pharma analyst Josh Schimmer realized that investors were struggling to place valuations on the leading COVID-19 vaccine developers, he pulled out the proverbial envelope,2020/8/14
-
Belgium's Ajinomoto doubles Indian small-molecule manufacturing cap with new facilityBelgian CDMO Ajinomoto Bio-Pharma Services has been on a run in recent of years expanding its operations around the world. That was the goal of an Indian joint venture buyout back in 2018—and nowAjin2020/8/14